Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy G. Chadwick Sells 1,383 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares of the company’s stock, valued at $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Kymera Therapeutics Price Performance

KYMR stock opened at $30.17 on Tuesday. The business has a 50-day moving average price of $38.81 and a 200 day moving average price of $43.66. The company has a market capitalization of $1.95 billion, a P/E ratio of -12.89 and a beta of 2.18. Kymera Therapeutics, Inc. has a 1-year low of $29.16 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Trading of Kymera Therapeutics

Several hedge funds have recently modified their holdings of KYMR. Wellington Management Group LLP lifted its position in shares of Kymera Therapeutics by 14.9% during the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after buying an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after buying an additional 650,000 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of Kymera Therapeutics during the fourth quarter valued at about $23,856,000. Boxer Capital Management LLC purchased a new stake in shares of Kymera Therapeutics during the fourth quarter valued at about $17,098,000. Finally, Jennison Associates LLC lifted its position in shares of Kymera Therapeutics by 85.8% during the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after buying an additional 368,394 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have commented on KYMR shares. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. UBS Group dropped their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Stephens reaffirmed an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Morgan Stanley lifted their target price on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 6th. Finally, BMO Capital Markets initiated coverage on Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 target price for the company. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $56.69.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.